SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America
Objective: The objective of the study is to examine the effect of sodium-glucose transporter 2 inhibitors (SGLT2) on proteinuria and renal function progression over 12 months in patients with proliferative lupus nephritis (LN). Material and methods: A retrospective observational analysis was conduct...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2025-04-01
|
| Series: | Nefrología Latinoamericana |
| Subjects: | |
| Online Access: | https://www.nefrologialatinoamericana.com/frame_eng.php?id=162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849430789083627520 |
|---|---|
| author | José L. Daza Gerardo Gutiérrez Rosa L. Peñuela-Murcia Andrés Cárdenas Juan S. Reyes-Bello |
| author_facet | José L. Daza Gerardo Gutiérrez Rosa L. Peñuela-Murcia Andrés Cárdenas Juan S. Reyes-Bello |
| author_sort | José L. Daza |
| collection | DOAJ |
| description | Objective: The objective of the study is to examine the effect of sodium-glucose transporter 2 inhibitors (SGLT2) on proteinuria and renal function progression over 12 months in patients with proliferative lupus nephritis (LN). Material and methods: A retrospective observational analysis was conducted on patients with LN in Argentina and Colombia. Patients diagnosed with class III or IV + V LN were followed for 12 months. Out of 95 biopsies of focal or diffuse proliferative LN, 74 histological samples met the inclusion criteria. These were divided into two groups: Group A included 35 patients who received conventional treatment plus SGLT2 inhibitors (empagliflozin 10 mg daily) and Group B included 39 patients who received only conventional treatment. Both groups received the same dose of cyclophosphamide and maintenance with mycophenolic acid. Laboratory findings, proteinuria behavior, and renal function progression were evaluated over 12 months. Results: Among the 74 patients, 64 were women (86.4%), with a mean age of 34 ± 12 years. Group A showed a reduction in proteinuria at 12 months to 0.48 (0.38-0.71) compared to Group B, which did not receive SGLT2 inhibitors, with proteinuria at 0.8 (0.42-1.3) (p = 0.02). Conclusions: Patients who received conventional immunosuppressive treatment and added SGLT2 inhibitors showed a reduction in proteinuria over a 12-month follow-up period.
|
| format | Article |
| id | doaj-art-2fbf2a39162d490581da2d64b18979d6 |
| institution | Kabale University |
| issn | 2444-9032 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Permanyer |
| record_format | Article |
| series | Nefrología Latinoamericana |
| spelling | doaj-art-2fbf2a39162d490581da2d64b18979d62025-08-20T03:27:51ZengPermanyerNefrología Latinoamericana2444-90322025-04-0122210.24875/NEFRO.24000019SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin AmericaJosé L. Daza0Gerardo Gutiérrez1Rosa L. Peñuela-Murcia2Andrés Cárdenas3Juan S. Reyes-Bello4Department of Nephrology, Hospital de Clínicas José de San Martin, Buenos Aires, ArgentinaDepartment of Nephrology, Hospital de Clínicas José de San Martin, Buenos Aires, ArgentinaDepartment of Epidemiology, Fundación Universitaria Ciencias de la Salud, Bogotá, ColombiaDepartment of Medicine, Cooperativa University, Bogotá, ColombiaDepartment of Medicine, Fundación Universitaria Sanitas, Bogotá, Colombia; 5Department of General Medicine, Hospital Federico Lleras Acosta, Ibagué, ColombiaObjective: The objective of the study is to examine the effect of sodium-glucose transporter 2 inhibitors (SGLT2) on proteinuria and renal function progression over 12 months in patients with proliferative lupus nephritis (LN). Material and methods: A retrospective observational analysis was conducted on patients with LN in Argentina and Colombia. Patients diagnosed with class III or IV + V LN were followed for 12 months. Out of 95 biopsies of focal or diffuse proliferative LN, 74 histological samples met the inclusion criteria. These were divided into two groups: Group A included 35 patients who received conventional treatment plus SGLT2 inhibitors (empagliflozin 10 mg daily) and Group B included 39 patients who received only conventional treatment. Both groups received the same dose of cyclophosphamide and maintenance with mycophenolic acid. Laboratory findings, proteinuria behavior, and renal function progression were evaluated over 12 months. Results: Among the 74 patients, 64 were women (86.4%), with a mean age of 34 ± 12 years. Group A showed a reduction in proteinuria at 12 months to 0.48 (0.38-0.71) compared to Group B, which did not receive SGLT2 inhibitors, with proteinuria at 0.8 (0.42-1.3) (p = 0.02). Conclusions: Patients who received conventional immunosuppressive treatment and added SGLT2 inhibitors showed a reduction in proteinuria over a 12-month follow-up period. https://www.nefrologialatinoamericana.com/frame_eng.php?id=162Lupus nephritis. Sodium-glucose cotransporter 2 inhibitors. Antinuclear antibodies. Systemic lupus erythematosus. |
| spellingShingle | José L. Daza Gerardo Gutiérrez Rosa L. Peñuela-Murcia Andrés Cárdenas Juan S. Reyes-Bello SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America Nefrología Latinoamericana Lupus nephritis. Sodium-glucose cotransporter 2 inhibitors. Antinuclear antibodies. Systemic lupus erythematosus. |
| title | SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America |
| title_full | SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America |
| title_fullStr | SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America |
| title_full_unstemmed | SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America |
| title_short | SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America |
| title_sort | sglt2 inhibitors in lupus nephritis a multicentric study in latin america |
| topic | Lupus nephritis. Sodium-glucose cotransporter 2 inhibitors. Antinuclear antibodies. Systemic lupus erythematosus. |
| url | https://www.nefrologialatinoamericana.com/frame_eng.php?id=162 |
| work_keys_str_mv | AT joseldaza sglt2inhibitorsinlupusnephritisamulticentricstudyinlatinamerica AT gerardogutierrez sglt2inhibitorsinlupusnephritisamulticentricstudyinlatinamerica AT rosalpenuelamurcia sglt2inhibitorsinlupusnephritisamulticentricstudyinlatinamerica AT andrescardenas sglt2inhibitorsinlupusnephritisamulticentricstudyinlatinamerica AT juansreyesbello sglt2inhibitorsinlupusnephritisamulticentricstudyinlatinamerica |